

# ESTP Newsletter 2023 (2)

Editor Amy Narewski

(ESTP contact link: <https://www.eurotoxpath.org/contact.php>)

Administrative Assistant to the ESTP EC



## Content

Calendar	1
The ESTP Council	2
President's Column	2
5th Cutting Edge Congress and 21st European Toxicological Pathology	3
ESTP Achievement Award	4
Do you know Toxicologic Pathology Forum?	5
Use of Whole Slide Imaging in Nonclinical Toxicology Studies: Q&A	6

calendar 2023	
<b><u>August 25-26</u></b>	TiHo Hannover/ sponsored by ESTP: Residency Programm, Toxicologic Pathology Training Program, Module „Cardiovascular System" (Hannover, Germany) <a href="#">LINK</a>
<b><u>August 31-September 2</u></b>	Joint European Congress of Veterinary Pathology and Clinical Pathology (ESVP/ECVP/ESVCP/ECVCP; Lisbon, Portugal) <a href="#">LINK</a>
<b><u>September 26</u></b>	IATP IATP Satellite Symposium Medical Device Safety Assessment: Pathology and Toxicology Perspectives (Basel, Switzerland) <a href="#">LINK</a>
<b><u>September 26-29</u></b>	20 <sup>th</sup> European Congress of Toxicologic Pathology: "Emerging Therapeutic Modalities: Gene and Cell Therapies, New Generation Biologics and Targeted Protein Degradation" (Basel, Switzerland) <a href="#">LINK</a>
<b><u>September 29-30</u></b>	ESTP 10th ESTP International Expert Workshop Designed to stay yet do no harm: Safety assessment of Long-Acting Injectables and the evaluation of the injection site (Basel, Switzerland) <a href="#">LINK</a>
<b><u>October 11-13</u></b>	Hungarian Tox Society: Annual Congress of the Hungarian Society of Toxicology (Sárvár, Hungary)
<b><u>November 15-16</u></b>	BSTP Annual Scientific Meeting; Preclinical translatability and pathology of cell-based therapies (Hosted by Evotec in Verona, Italy) <a href="#">LINK</a>
<b>2024</b>	
<b><u>August 28-31</u></b>	5 <sup>th</sup> Cutting Edge Pathology Congress (ESTP, ECVP/ESVP), Neuropathology: The vast Pink Wonderland (Madrid, Spain) <a href="#">LINK</a>

## The ESTP council

<i>Chairwoman</i>	Silvia Guionaud	<i>Secretary</i>	Raffaella Capobianco
<i>Vice President</i>	Lars Mecklenburg	<i>Treasurer</i>	Kuno Würsch
<i>Past Chairman</i>	Franck Chanut	<i>Designated Chairwoman</i>	Vanessa Schumacher
<i>Congress councillor</i>	Anna-Lena Frisk	<i>Councillor digital pathology</i>	Lise Bertrand
<i>Councillor for academia</i>	Ingo Gerhauser	<i>Councillor early career pathologists</i>	Simone Tangermann
<i>Councillor for nomenclature</i>	Ute Bach	<i>Councillor for electronic communication</i>	Rupert Kellner
<i>BSTP Representative</i>	Zuhal Dincer	<i>DSTP Representative</i>	Eveline de Rijk
<i>HSTP Representative</i>	György Selenyi	<i>FSTP Representative/ Toxicologic Pathology journal liaison</i>	Béatrice Gauthier
<i>STP liaison, chair of the scientific and regulatory standards committee</i>	Annette Romeike	<i>Chair, awards committee</i>	Hans Harlemann
<i>Chair, Pathology 2.0 working group</i>	Dirk Schaudien	<i>Chair, clinical pathology committee</i>	Monika Keresztes
<i>Society admin</i>	Amy Narewski		

### President's Column

Dear ESTP members,

Summer is in full swing and in fact, some parts of Europe are sweltering with heat. My thoughts go out to those of you who have to work under these conditions- please be safe!

The Executive Committee has continued working on the results of our SWOT analysis, with results that tie into our joint work at the last ESTP conference. Engaging and catering to Early Career Pathologists is emerging as a central point, and we have made great strides this year to intensify our work in this area. In July, Laura Polledo, Johannes Junginger and I will attend the ECVP Summer School for an

ESTP sponsored evening of pizza and professional advice.

At the same time, our collaboration with STP and BSTP on our joint official journal *Toxicologic Pathology* are undergoing a review and update. Review and submission of ESTP sponsored manuscripts is an important part of this. As a professional society, one of our remits is to foster scientific discourse and investigation, convene experts and commission or sponsor manuscripts. The Expert Workshop has been an excellent example, and the Pathology 2.0 working group is another one. If you are planning a publication that might be eligible for ESTP sponsorship, please get in touch with us – the earlier, the better!

And, talking of Pathology 2.0, have you seen the wonderful [article](#) from Josep Monné and co-

authors on in situ hybridization? It presents a broad overview of current state-of-the-art, technical prerequisites and applications. Congratulations to the authors for bringing this topic to life this.

We are now entering the time period running out to our annual conference, which will be held in Basel from 26<sup>th</sup> to the 29<sup>th</sup> September. Have you registered yet? Once again, the conference is flanked by an IATP seminar and an Expert workshop, which also deserve your attention. Preparing for our Annual General Meeting, we are looking at some minor changes to our constitution. These reflect in part the change from the term “young pathologists” to “early career pathologists”. The other change is on the number of EC member signatures required for certain activities, like submitting our accounts. Please take some time to look at the proposed changes and make your opinion known.

I wish you an enjoyable summer, hopefully with some nice, sunny (but not too hot) holidays and look forward to seeing you in Basel in September!

Silvia Guionaud  
ESTP Chairwoman  
[silvia.guionaud@guionaudconsulting.com](mailto:silvia.guionaud@guionaudconsulting.com)

**5th Cutting Edge Congress and  
21st European Toxicological Pathology**  
“Neuropathology: The Vast Pink  
Wonderland.”

Dear Colleagues,

On behalf of the ESTP and the scientific organizing committee (SOC), we are pleased to provide you with an update on the upcoming 21st European Toxicological Pathology/5th Cutting Edge Congress, scheduled to take place near Madrid, Spain, from August 28 to 31<sup>st</sup> 2024. This congress will be held in conjunction with ESVP and ECVP, and the ESTP chosen theme is "Neuropathology: The Vast Pink Wonderland."

Neuropathology is an incredibly fascinating and complex field, encompassing both preclinical and clinical aspects of assessment and therapy. Neurodegenerative diseases serve as a prime example of how impactful neuropathology can be in our daily lives, not to mention the renewed interest in CNS diseases like Alzheimer's, since a number of new drugs received marketing authorization last year.

The SOC for the 2024 congress has already begun working on topics of interest, and neurodegenerative diseases will definitely be one of the subjects covered during the event. Of course, this is not the only topic that will be explored and we are "brainstorming" on other areas of significant interest, such as oligonucleotides and new approaches to CNS examination.

Have you become interested in forming part of the SOC for 2024? Please do not hesitate to

contact the ESTP (link at top of newsletter) and join the next SOC meeting.

We strongly encourage you to mark your calendars for next year's congress.

Prepare to immerse yourself in the vast pink wonderland like never before!

Sincerely,  
Scientific Organising committee

### **ESTP Achievement Award**

Dear colleagues,

The ESTP Executive Committee (EC) has recently discussed how to honour outstanding activity in the field of Toxicologic Pathology without offering too many Honorary Memberships and weakening this honorary status.

To facilitate the decision-making process, we created a survey which was submitted to the EC members, including us.

Results from the survey were discussed during April's monthly meeting of the EC and it was agreed that Honorary Membership endorsements should not be abolished but a nomination will only be possible on exceptional basis, possibly every five years. This was decided keeping in mind that the Honorary Membership status should remain exceptional for outstanding services to our Society.

We take the chance here to recall that, according to our Constitution, honorary members can be proposed by an ESTP member and should fulfil the following criteria: individual ESTP members who have rendered outstanding services to the society and/or the field of toxicologic pathology.

In practice, the EC revises if the candidate is appropriate by checking the criteria and decides if the candidate can be recommended. The recommendations of the EC are presented by the President and Secretary for acclamation during the annual general assembly.

Hence, we felt the need to recognize our ESTP members who are making an outstanding contribution to our profession. We agreed to implement a so called "Achievement Award" which will be granted upon individual ESTP members who have best rendered in either one or more of the following four topics:

- services to society
- mentoring younger generation
- lecturing
- science

We hope that this new initiative will be well perceived by you! You can propose a candidate! One or two achievement awards per year will be possible. The EC will review the proposed candidates from the membership and decide who to recommend. The recommendations of the EC are presented by President and Secretary for acclamation by the AGA and we will make sure to profile the newly recognized member in this newsletter!

Raffaella Capobianco (ESTP Secretary) & Hans Harleman (Chair of the Award Committee)

**Do you know  
Toxicologic Pathology Forum?**

Toxpath Forum provides a venue for the presentation of topics with potential relevance to toxicologic pathology, for the sole purpose of initiating discussion or presenting perspectives not previously considered. The TPF committee has been created and is coordinated by the Society of Toxicologic Pathology but includes representation from the BSTP and ESTP. The format and subject matter of TPF articles vary, but generally these are short opinion pieces that provide author perspectives on regulatory issues and strategies related to nonclinical toxicology testing and risk assessment.

Toxicologic Pathology Forum occasionally publishes full or short topical articles or reviews (including technical reviews), and commentaries on draft and final regulatory guidance, or announcements and events related to regulatory or nonregulatory issues of interest to toxicologic pathologists. Articles can originate in a number of ways: via request from the TPF committee to the potential authors, or unsolicited through author(s) submission directly to the TPF committee or by direct submission to the Toxicologic Pathology journal.

The TPF review timeline and process is expedited compared to other types of articles. The review is generally limited to 5 or 6 TPF committee members and occasionally other STP members or content experts, if deemed necessary by the TPF committee. The review typically focuses on readability and relevance to the readership, with feedback generally offered as primarily discretionary with limited impact on acceptability. A 'shepherd' is attributed to each

manuscript in order to guide the author throughout the process until the submission to the Toxicologic Pathology journal.

To avoid confusion with STP-endorsed publications such as Best Practice articles, TPF articles have the article type incorporated into the title and a clear disclaimer indicating that these are personal opinions of the authors that are not endorsed by the STP, BSTP, or ESTP, or the authors' respective organizations, employers, or regulatory agencies.

Overall, Toxpath Forum provides a space of freedom for the toxicologic pathology community with thoughtful articles on a variety of hot topics: adversity, digitalization, blinded vs not blinded, use of controls... and more to come thanks to YOU.

# Use of Whole Slide Imaging in Nonclinical Toxicology Studies: Questions and Answers

*Guidance for Industry*



MAY 2023

## Use of Whole Slide Imaging in Nonclinical Toxicology Studies: Q&A

Dear ESTP members,

The U.S. FDA recently published the final guidance document on the use of Whole Slide Imaging, which is available on [their website](#).

This final document contains significant differences from the draft version that was submitted for comments in 2022. The main changes the Digital Pathology committee would like to draw your attention to are:

- The FDA does not consider the 2-D whole slide image (WSI) to be an exact copy of the glass slide,
- WSIs assessed by the study pathologist should be retained if they are **used to generate raw data** (*i.e.*, contemporaneous peer review is out of scope),
- When WSIs are used to generate raw data, protection should prevent loss/alteration of data, maintain chain of custody, control access and secure data systems and data transmission,
- The pathologist should not alter permanently the original image file,

while they can make non-permanent adjustments that need not be retained.

We recommend ESTP members read carefully the above guidance, and all are welcome to contact the Digital Pathology committee (see ESTP contact details at top of newsletter) should questions or comments arise.

Wishing you a good summer reading!  
For the Digital Pathology Committee,

Lise Bertrand